Taking stock of the drug industry, from the lab to the medicine chest

December 11, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe FDA approves first new gonorrhea drug in decades The drug, Blujepa, is from a new class of antibiotics, the first in decades to be approved as a treatment for gonorrhea. By Helen Branswell STAT+ | Lilly's next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations Some participants in the trial discontinued the drug because they were losing too much weight, an emerging concern with obesity medicines. By Elaine Chen STAT+ | Europe's pharma policy shakeup moves forward toward enactment Policymakers unveiled an agreement, which still needs to be voted on, that aims to encourage innovation while improving access to drugs. By Andrew Joseph Molly Ferguson/STAT STAT+ | Wave's 'gym bro' obesity drug is story over substance Wave is selling a story that is proving irresistible to investors looking for the next big thing in obesity. By Adam Feuerstein ASH 2025 recap: what you need to know from the big medical meeting American Society of Hematology conference serves up latest research to thousands of attendees: Alex Hogan breaks it down in this week's STATus Report. By Alex Hogan Opinion: Now is the time to launch mpox vaccine booster trials It's unclear how long the two-dose Jynneos vaccine for mpox offers protection. With cases of mpox clade I in the U.S., we need answers. By Joseph Osmundson and Miguel I. Paredes

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser